{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:51:03Z","timestamp":1776873063460,"version":"3.51.2"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The effectiveness of direct acting antiviral (DAA) therapy in patients with active hepatocellular carcinoma (HCC) is poorly defined. NHS England approved DAA therapy for all viraemic patients, including those with HCC. The aim of this retrospective study is to provide a real\u2010life data of treatment outcomes in those with active HCC. Patients with HCV related HCC from the National Hepatitis C registry in South\u2010East England between 2016 and 2023 were included. The primary outcome was to assess the HCV care cascade in patients with HCV related HCC (HCC cohort) in comparison with those with advanced fibrosis\/cirrhosis without HCC (non\u2010HCC cohort). 1518 HCV RNA\u2010positive patients started DAA therapy. 92.4% (1403) were included in the non\u2010HCC cohort and 7.6% (115) were included in the HCC cohort. The SVR rate in the HCC cohort was 87% (80\/92) versus 94.5% (1126\/1191) in the non\u2010HCC cohort (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003). In the multivariate analysis, only the presence of HCC (OR 0.4 95% CI 0.2\u20130.9;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.029) was associated with a lower probability of achieving SVR. SVR rates were 95.6%, 50%, 75% and 22.2% and the median overall survival (OS) was 80, 29, 17 and 3\u2009months for BCLC 0\u2010A\/B\/C\/D respectively. OS was longer in those who achieved SVR. More than two thirds of patients with HCV\u2010related HCC initiated and completed DAA therapies. This high level of treatment uptake has led to an acceptable cure rate. Treating patients with HCV and HCC should be viewed as an appropriate clinical standard to improve overall outcomes. However, DAA therapy should not be initiated in those with a short life expectancy.\n                  <\/jats:p>","DOI":"10.1111\/jvh.70148","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T14:50:17Z","timestamp":1770735017000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Setting the Record Straight: Utility and Outcomes in Patients With\n                    <scp>HCV<\/scp>\n                    Related\n                    <scp>HCC<\/scp>"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9708-8245","authenticated-orcid":false,"given":"Mar\u00eda Fernanda","family":"Guerra\u2010Veloz","sequence":"first","affiliation":[{"name":"Institute of Liver Studies King's College Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sital","family":"Shah","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies King's College Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Emmanouil","sequence":"additional","affiliation":[{"name":"NHS England &amp; NHS Improvement HCV Elimination  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Olsen","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies King's College Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renita","family":"George","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies King's College Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Selemani","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies King's College Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Oncology King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Carey","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies King's College Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Mehta","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies King's College Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Gillyon\u2010Powell","sequence":"additional","affiliation":[{"name":"NHS England &amp; NHS Improvement HCV Elimination  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4754-828X","authenticated-orcid":false,"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies King's College Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"WHO \u201cGlobal Health Sector Strategies on Respectively HIV Viral Hepatitis and Sexually Transmitted Infections for the Period 2022\u20132030.\u201d"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)01320\u2010X"},{"key":"e_1_2_10_4_1","unstructured":"World Health Organisation (WHO) \u201cHepatitis C\u2014Key Facts \u201dhttps:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/hepatitis\u2010c."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.021"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)32111\u20101"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32758"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14685"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.04.017"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.008"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.046"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.02.046"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814404"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100578"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101567"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560\u20107917"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.020"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.03.027"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2019.09.006"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.1015"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro\u20102022\u2010102373"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.025"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30988"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70362"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad319"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.70148","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T08:35:50Z","timestamp":1772958950000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.70148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/jvh.70148"],"URL":"https:\/\/doi.org\/10.1111\/jvh.70148","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"2025-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70148"}}